Welcome to our dedicated page for POINT Biopharma Global news (Ticker: PNT), a resource for investors and traders seeking the latest updates and insights on POINT Biopharma Global stock.
POINT Biopharma Global Inc. (PNT) is a novel biotechnology company dedicated to the development and commercialization of radiopharmaceutical products, which are designed to address unmet patient needs in oncology. Based in Indianapolis, POINT has established itself as a key player in precision oncology by leveraging cutting-edge technologies and a robust pipeline of radioligand therapies.
POINT's primary focus is on radioligand therapy (RLT), a targeted treatment that combines a radioactive isotope with a molecule that binds specifically to cancer cells. One of the company's flagship projects includes 177Lu-PNT2002, an advanced prostate-specific membrane antigen (PSMA)-targeted RLT for treating metastatic castration-resistant prostate cancer (mCRPC). The Phase 3 SPLASH study recently demonstrated that 177Lu-PNT2002 significantly improves radiographic progression-free survival, showcasing its potential to become a vital treatment option for patients who have progressed on androgen receptor pathway inhibitors.
POINT Biopharma's extensive pipeline also includes other promising candidates, supported by robust in-house manufacturing capabilities and secured supplies of medical isotopes like actinium-225 and lutetium-177. This ensures a reliable production and distribution network, critical for advancing clinical development and commercialization efforts.
The company's financial condition and strategic partnerships have been strengthened by significant milestones. Notably, POINT Biopharma is in the process of being acquired by Eli Lilly and Company (NYSE: LLY) for approximately $1.4 billion, equating to $12.50 per share in cash. This acquisition, supported by the U.S. Nuclear Regulatory Commission's consent for the transfer of POINT's radioactive materials license, is expected to close by the end of 2023, pending the satisfaction of customary closing conditions. As of December 2023, the tender offer has seen substantial shareholder participation, with over 67% of shares tendered.
Founded on a vision of transforming cancer treatment, POINT Biopharma's commitment to innovative therapies and strategic growth positions it as a leader in the radiopharmaceutical industry. The company's alignment with Eli Lilly, a pioneer in life-changing biotechnology and pharmaceuticals, is set to further enhance its capabilities and reach, promising better outcomes for cancer patients worldwide.
POINT Biopharma Global Inc. (NASDAQ: PNT) has received a No-Objection Letter from Health Canada, allowing the initiation of a Phase 1 clinical trial for PNT2004. This trial will leverage 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy in patients with select solid tumors, including colorectal and pancreatic cancers. The trial is set to begin in summer 2022, with dosing starting at 4 GBq. The primary goal is to identify the maximum tolerated dose. Initial data is expected in early 2023, marking a significant step in the company's FAP-α targeted radiopharmaceutical program.
POINT Biopharma Global (NASDAQ: PNT) announced key milestones in its Phase 3 SPLASH trial, now expanding to the EU, and filed a CTA in Canada for PNT6555. The company's manufacturing facility commenced supplying doses for the trial. With $227.4 million in cash as of March 31, 2022, POINT's operations are funded into early 2024. However, the company reported a net loss of $16.4 million for Q1 2022, up from $5.8 million in Q1 2021, with R&D expenses rising to $12.5 million. Positive momentum continues with promising data from ongoing trials.
POINT Biopharma Global Inc. (NASDAQ: PNT) confirmed that its SPLASH clinical trial for the PSMA targeted 177Lu-PNT2002 program is on schedule, with no drug supply issues reported. The company emphasizes its robust supply chain capabilities to ensure timely delivery of radiopharmaceuticals. Recruitment for the Phase 3 trial is ongoing in North America and Europe, with top-line data expected by mid-2023. POINT's commitment to reliability and redundancy in manufacturing aims to address any potential disruptions in drug supply.
POINT Biopharma has initiated randomization in its Phase 3 SPLASH trial for pre-chemo metastatic castration-resistant prostate cancer (mCRPC) across North America and Europe. The first patient in the EU has been dosed, with a total of 37 sites now enrolling. The trial is utilizing 177Lu-PNT2002, a PSMA-targeted radioligand, with top-line data expected mid-2023. This milestone marks significant progress since the trial’s inception in September 2021, demonstrating POINT's commitment to innovating cancer treatments.
POINT Biopharma Global (NASDAQ: PNT) has announced a phase 1 clinical trial for its investigational radiopharmaceutical PNT6555, aimed at targeting Fibroblast Activation Protein (FAP) for cancer imaging and therapy. The trial is set to begin in summer 2022 in Canada and utilizes 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapeutic purposes. Findings show that 68Ga-PNT6555 effectively targets tumors with low normal tissue retention, while 177Lu-PNT6555 exhibits prolonged tumor retention. The research highlights the potential of FAP as a pan-cancer target.
POINT Biopharma Global reported significant developments in its pan-cancer therapeutic programs, particularly for PNT2004 and PNT2001. The company showcased promising phase 1 trial data for PNT6555 in the SPLASH trial, with top-line results expected mid-2023. As of December 31, 2021, POINT held approximately $238.8 million in cash, sufficient to fund operations into early 2024, despite experiencing an increased net loss of $45.9 million for the year. With a robust pipeline and a newly operational manufacturing facility in Indianapolis, POINT aims to accelerate its clinical advancements in 2022.
POINT Biopharma Global Inc. (PNT) announced that recent geopolitical events and a reactor shutdown in Europe have not impacted its trial timelines or 2022 business outlook. Point's CEO emphasized the strength of their radioisotope supply chain, which has proven resilient amid industry challenges. The company continues recruitment for its Phase 3 SPLASH trial evaluating PNT2002 for treating metastatic castration-resistant prostate cancer, expecting to report top line data by mid-2023. POINT’s robust supply chain management is highlighted as a key factor in maintaining operational stability.
POINT Biopharma Global Inc. (NASDAQ: PNT) announced favorable dosimetry results for PNT2002 in a Phase III study focused on metastatic castrate-resistant prostate cancer (mCRPC). Dr. Jean-Mathieu Beauregard presented these findings at the SNMMI Mid-Winter Annual Meeting. The company will host a free educational webinar on radiopharmaceutical dosimetry on March 29, 2022, led by Dr. Ana Kiess. This session aims to clarify dosimetry's role in optimizing treatment safety and efficacy for cancer therapies. Registration is available online to encourage investor participation.
POINT Biopharma Global Inc. (NASDAQ: PNT) recently published favorable dosimetry data for its Phase 3 SPLASH trial evaluating PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that red marrow dosimetry was significantly below critical thresholds, suggesting a promising avenue for combination therapies. This trial involves approximately 400 patients across North America and Europe, with the primary endpoint being radiographic progression-free survival (rPFS). Top-line results are expected mid-2023.
POINT Biopharma Global Inc. (NASDAQ: PNT) announced CEO Dr. Joe McCann's participation in upcoming investor conferences. Notable events include:
- B. Riley Securities’ Radiation Oncology Investor Day: February 22, 2022, 11:30 AM ET (Fireside chat)
- Cowen & Co. Annual Health Care Conference: March 8, 2022, 10:30 AM ET (Panel discussion)
- Oppenheimer & Co. Annual Health Care Conference: March 17, 2022, 2:00 PM ET (Virtual presentation)
Webcasts will be available on the company’s website.
FAQ
What is the market cap of POINT Biopharma Global (PNT)?
What is POINT Biopharma Global Inc. (PNT)?
What are radiopharmaceutical products?
What is 177Lu-PNT2002?
How did 177Lu-PNT2002 perform in clinical trials?
Who is acquiring POINT Biopharma?
When is the acquisition by Eli Lilly expected to close?
What approvals were needed for the POINT Biopharma acquisition?
What are some key achievements of POINT Biopharma?
What does the acquisition mean for POINT Biopharma's future?
Where can investors find more information about the tender offer?
